← Product Code [DGC](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DGC) · K964152 # UNICAP TOTAL IGE ASSAY/PHARMACIA TOTAL IGE CONTROLS LMH (K964152) _Pharmacia, Inc. · DGC · Apr 23, 1997 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DGC/K964152 ## Device Facts - **Applicant:** Pharmacia, Inc. - **Product Code:** [DGC](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DGC.md) - **Decision Date:** Apr 23, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5510 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Intended Use UniCAP Total IgE Flurorimmunoassay is an in vitro assay for the quantitative measurement of circulating total IgE in human serum or plasma. UniCAP Total IgE assay is to be used with the instrument UniCAP 100. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories, as well as, physician office laboratories. Pharmacia Total IgE Control LMH is intended for laboratory use in monitoring the performance of total IgE measurements as determined by Phadebas IgE PRIST /Phadezym IgE PRIST, Pharmacia IgE RIA, Pharmacia IgE RIACT, Pharmacia CAP System IgE RIA/FEIA and UniCAP Total IgE. ## Device Story UniCAP 100 is a fully integrated, automated system for in vitro diagnostic measurement of total IgE in human serum or plasma. System processes samples and reagents via ImmunoCAP; performs all handling steps; completes analysis in 2.5 hours. Instrument software manages calibration curves, stores curves for up to one month, and validates assay runs using Curve Controls. System automatically prints laboratory reports. Used in clinical and physician office laboratories by laboratory personnel. Output provides quantitative IgE levels to assist clinicians in diagnosing IgE-mediated allergic disorders. ## Clinical Evidence Bench testing only. Comparison study of 150 serum samples across the full measuring range compared UniCAP 100/UniCAP Total IgE Assay against the Pharmacia CAP System. Results showed a correlation coefficient of 0.99 with linear regression y = 24.5 + 1.05x. ## Technological Characteristics Fully automated fluoroimmunoassay system. Includes UniCAP 100 instrument, UniCAP RM external software, and specific reagents (Total IgE Conjugate, Anti-IgE ImmunoCAP). Employs stored calibration curves valid for one month, verified by run-specific Curve Controls. System handles sample/reagent processing and automated result calculation. ## Regulatory Identification An immunoglobulins A, G, M, D, and E immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the immunoglobulins A, G, M, D, an E (serum antibodies) in serum. Measurement of these immunoglobulins aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents. ## Predicate Devices - Pharmacia CAP System IgE FEIA ## Reference Devices - Phadebas IgE PRIST - Phadezym IgE PRIST - Pharmacia IgE RIA - Pharmacia IgE RIACT - Pharmacia CAP System IgE RIA/FEIA ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K964152 UNiCAP Total IgE 510(k) Submission Section 11. Summary of Safety and Effectiveness APR 23 1997 # 11. SUMMARY OF SAFETY AND EFFECTIVENESS This summary of safety and effectiveness information is being submitted in accordance with the requirements of The Safe Medical Devices Act of 1990 (SMDA 1990). Date of Summary Preparation: October 10, 1996 Distributor: Pharmacia & Upjohn Manufacturer: Pharmacia AB S-751 82 Uppsala, Sweden Company Contact Person: Shelley A. Beadle Pharmacia & Upjohn Director, Regulatory Affairs 9200-298-109 7000 Portage Road Kalamazoo, MI 49001-0199 Device Names: UniCAP Total IgE Fluoroimmunoassay Pharmacia Total IgE Control LMH Common Name: In vitro quantitative assay for the measurement of circulating total IgE. Classification: | Product Name | Product Code | Class | CFR | | --- | --- | --- | --- | | UniCAP Total IgE Fluorimmunoassay | 82DGC | II | 866.5510 | | Pharmacia Total IgE Control LMH | 82DGC | II | 866.5510 | Substantial Equivalence to: Assay: Pharmacia CAP System IgE FEIA Control Sera: Phadexact Serum Total IgE Controls, Low, Medium, High utsec11.doc 10/14/96 02-00071 {1} UniCAP Total IgE 510(k) Submission Section 11. Summary of Safety and Effectiveness ## Intended Use Statements: 1. UniCAP Total IgE Flurorimmunoassay is an in vitro assay for the quantitative measurement of circulating total IgE in human serum or plasma. UniCAP Total IgE assay is to be used with the instrument UniCAP 100. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories, as well as, physician office laboratories. 2. Pharmacia Total IgE Control LMH is intended for laboratory use in monitoring the performance of total IgE measurements as determined by Phadebas IgE PRIST /Phadezym IgE PRIST, Pharmacia IgE RIA, Pharmacia IgE RIACT, Pharmacia CAP System IgE RIA/FEIA and UniCAP Total IgE. ## General Description: UniCAP is a fully integrated and automated system for the determination of total IgE in human blood serum or plasma. The UniCAP system includes the UniCAP 100 instrument with software for immunodiagnostic testing; UniCAP RM External Software; UniCAP reagents, in this submission reagents for the measurement of total IgE, and Pharmacia Total IgE Control LMH. The UniCAP 100 instrument is designed to handle all steps from sample and reagent handling to processing of results. Reagents, requests, samples and ImmunoCAP are loaded into the instrument and the process, which takes 2.5 hours is started. A laboratory report is automatically printed when the process is ended. UniCAP 100 can store a calibration curve to be used for up to one month. After an initial calibration curve is accepted by the software, subsequent assay runs may use the stored calibration curve for calculation of results. In these runs, Curve Controls are included to validate that the run is on the same response level as the stored curve. Limits for the response of the Curve Controls are defined in the UniCAP 100 Operator and Panel Software. A new calibration curve is run once a month, and/or when a new lot number of Total IgE Conjugate or Anti- IgE ImmunoCAP is introduced. utsec11.doc 10/14/96 02-00072 {2} UniCAP Total IgE 510(k) Submission Section 11. Summary of Safety and Effectiveness ## Device Comparison: UniCAP Total IgE Fluoroimmunoassay reagents when used with the UniCAP 100 Instrument are substantially equivalent to another commercially available assay and instrumentation system for the measurement of total IgE, namely Pharmacia CAP System IgE FEIA used with Pharmacia CAP System instrumentation. ## Comparison Data: Comparison studies were performed to establish the substantial equivalence of results using UniCAP 100 and UniCAP Total IgE Assay compared to the corresponding instrumentation and reagents in Pharmacia CAP System. The comparison study comprised 150 serum samples with concentrations spread over the complete measuring range of the assay. Linear regression analysis gives the equation $y = 24..5 + 1.05x$, where $y$ represents UniCAP and $x$ represents Pharmacia CAP System. The correlation coefficient is 0.99. Therefore, Pharmacia & Upjohn concludes that the two systems show excellent correlation, and are substantially equivalent. utsec11.doc 10/14/96 02-00073 --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DGC/K964152](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DGC/K964152) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com